Szucs, Thomas D <br/><br/>
Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.  [electronic resource] 

 -  Cardiovascular drugs and therapy  Jun 2006 
 - 193-204 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0920-3206 
<br/><br/><label>Standard No.: </label>10.1007/s10557-006-8282-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Cost-Benefit Analysis<br/>Eplerenone<br/>Female<br/>Health Care Costs<br/>Humans<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--complications<br/>Spironolactone--analogs & derivatives<br/>Ventricular Dysfunction, Left--drug therapy